These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

258 related articles for article (PubMed ID: 19155198)

  • 21. Androgen axis in prostate cancer.
    Culig Z; Bartsch G
    J Cell Biochem; 2006 Oct; 99(2):373-81. PubMed ID: 16598769
    [TBL] [Abstract][Full Text] [Related]  

  • 22. New Opportunities for Targeting the Androgen Receptor in Prostate Cancer.
    Centenera MM; Selth LA; Ebrahimie E; Butler LM; Tilley WD
    Cold Spring Harb Perspect Med; 2018 Dec; 8(12):. PubMed ID: 29530945
    [TBL] [Abstract][Full Text] [Related]  

  • 23. The androgen receptor as putative therapeutic target in hormone-refractory prostate cancer.
    Kageyama Y; Hyochi N; Kihara K; Sugiyama H
    Recent Pat Anticancer Drug Discov; 2007 Nov; 2(3):203-11. PubMed ID: 18221063
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Manipulation of androgens and alterations in the androgen receptor axis in prostate cancer.
    Nguyen MM; Wang Z
    Minerva Urol Nefrol; 2008 Mar; 60(1):15-29. PubMed ID: 18427432
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Castration-resistant prostate cancer: locking up the molecular escape routes.
    Attar RM; Takimoto CH; Gottardis MM
    Clin Cancer Res; 2009 May; 15(10):3251-5. PubMed ID: 19447877
    [TBL] [Abstract][Full Text] [Related]  

  • 26. The androgen receptor in hormone-refractory prostate cancer.
    Mao HL; Zhu ZQ; Chen CD
    Asian J Androl; 2009 Jan; 11(1):69-73. PubMed ID: 19050686
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Novel, potent anti-androgens of therapeutic potential: recent advances and promising developments.
    Vasaitis TS; Njar VC
    Future Med Chem; 2010 Apr; 2(4):667-80. PubMed ID: 21426013
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Androgen receptor as a target in androgen-independent prostate cancer.
    Balk SP
    Urology; 2002 Sep; 60(3 Suppl 1):132-8; discussion 138-9. PubMed ID: 12231070
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Androgen Receptor Signaling Pathway in Prostate Cancer: From Genetics to Clinical Applications.
    Aurilio G; Cimadamore A; Mazzucchelli R; Lopez-Beltran A; Verri E; Scarpelli M; Massari F; Cheng L; Santoni M; Montironi R
    Cells; 2020 Dec; 9(12):. PubMed ID: 33321757
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Androgen receptor: role and novel therapeutic prospects in prostate cancer.
    Taplin ME
    Expert Rev Anticancer Ther; 2008 Sep; 8(9):1495-508. PubMed ID: 18759700
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Hormone treatment for prostate cancer: current issues and future directions.
    Ichikawa T; Suzuki H; Ueda T; Komiya A; Imamoto T; Kojima S
    Cancer Chemother Pharmacol; 2005 Nov; 56 Suppl 1():58-63. PubMed ID: 16273367
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Novel Insights into Molecular Indicators of Response and Resistance to Modern Androgen-Axis Therapies in Prostate Cancer.
    Silberstein JL; Taylor MN; Antonarakis ES
    Curr Urol Rep; 2016 Apr; 17(4):29. PubMed ID: 26902623
    [TBL] [Abstract][Full Text] [Related]  

  • 33. The role of the androgen receptor in the development and progression of prostate cancer.
    Jenster G
    Semin Oncol; 1999 Aug; 26(4):407-21. PubMed ID: 10482183
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Lessons from in-vivo models of castration-resistant prostate cancer.
    Lin D; Gout PW; Wang Y
    Curr Opin Urol; 2013 May; 23(3):214-9. PubMed ID: 23385975
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Acquisition of agonistic properties of nonsteroidal antiandrogens after treatment with oncostatin M in prostate cancer cells.
    Godoy-Tundidor S; Hobisch A; Pfeil K; Bartsch G; Culig Z
    Clin Cancer Res; 2002 Jul; 8(7):2356-61. PubMed ID: 12114440
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Mechanisms of endocrine therapy-responsive and -unresponsive prostate tumours.
    Culig Z; Steiner H; Bartsch G; Hobisch A
    Endocr Relat Cancer; 2005 Jun; 12(2):229-44. PubMed ID: 15947099
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Androgen receptor signaling in androgen-refractory prostate cancer.
    Grossmann ME; Huang H; Tindall DJ
    J Natl Cancer Inst; 2001 Nov; 93(22):1687-97. PubMed ID: 11717329
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Antiandrogens in prostate cancer endocrine therapy.
    Culig Z; Bartsch G; Hobisch A
    Curr Cancer Drug Targets; 2004 Aug; 4(5):455-61. PubMed ID: 15320720
    [TBL] [Abstract][Full Text] [Related]  

  • 39. [Molecular mechanisms involved in hormone resistance of prostate cancer].
    Cabrespine A; Guy L; Chollet P; Debiton E; Bay JO
    Bull Cancer; 2004 Oct; 91(10):747-57. PubMed ID: 15556875
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Androgen receptor variant-driven prostate cancer: clinical implications and therapeutic targeting.
    Antonarakis ES; Armstrong AJ; Dehm SM; Luo J
    Prostate Cancer Prostatic Dis; 2016 Sep; 19(3):231-41. PubMed ID: 27184811
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 13.